Prevention of lymphotropic hepatitis C virus infection by blocking antibodies

通过阻断抗体预防淋巴细胞性丙型肝炎病毒感染

基本信息

批准号：
11670512
负责人：
HAYASHIDA Kazuhiro
金额：
$ 2.18万
依托单位：
KYUSHU UNIVERSITY
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
1999
资助国家：
日本
起止时间：
1999 至 2000
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-11670512/
关键词：
Chronic hepatitis C HCV Cell tropism lymphocyte blocking antibody interferon

项目摘要

We measured the binding ability of chronic hepatitis C virus (HCV) to the lymphocyte cell line HPB-Ma in the patient's serum, and found that it was one of the major determinant of interferon therapy by the prospective study of 152 consecutively enrolled patients (J Hepatology). As the HCV loose their infectivity by neutralized antibodies, we measured the quantity of antibody-free virion in the serum, and determined the amino acid sequence of hypervariable region of envelope 2 protein for the 38 patients ; 22 genotype 1b and 16 genotype 2a/2b. We found the consensus sequence of hypervariable region in the genotype 1b patients with a small amount of antibody-free virion and the all patients with a genotype 2a/2b infection regardless of the quantity of antibody-free virion, but not in the genotype 1b patients with a high amount of antibody-free virions (J Med Virol).To determine the cell tropism of HCV, we established the measurement method of HCV that bound to the hepatocyte cell line HuH7. The HCV in the majority of patients could bind to the both cell lines HPB-Ma and HuH7, while the HCV in some patients could bind only to the hepatocyte cell line HuH7. There are no HCV that could bind only to the lymphocyte cell line HPB-Ma. The interferon treatment efficacy was well related not to the binding ability to the hepatocyte cell line HuH7 but to the lymphocyte cell line HPB-Ma. Now, we are examining the hypervariable region to analyze the cell tropism and the blocking antibody against the lymphocyte infection.

我们测量了慢性乙型肝炎病毒（HCV）与患者血清中淋巴细胞细胞系HPB-MA的结合能力，发现它是152个连续招募的患者（J HEPATOLOGY）的前瞻性研究通过前瞻性研究的主要决定因素之一。由于HCV通过中和抗体松散其感染性，因此我们测量了血清中无抗体的病毒粒子的数量，并确定了38名患者的包膜2蛋白的高变量区域的氨基酸序列； 22基因型1B和16个基因型2A/2B。我们发现，无抗体无抗体病毒素的基因型1B患者的高变量区域的共识序列，而所有患有基因型2A/2B感染的患者，无论无抗体无抗体病毒体的量如何，在基因型1B患者中却没有大量的无抗体病毒体（j Med virol）。与肝细胞细胞系HUH7结合。大多数患者的HCV都可以与两个细胞系HPB-MA和HUH7结合，而某些患者的HCV只能与肝细胞细胞系HUH7结合。没有HCV可以仅与淋巴细胞细胞系HPB-MA结合。干扰素治疗疗效与肝细胞细胞系HUH7的结合能力无关，而与淋巴细胞细胞系HPB-MA有关。现在，我们正在检查可分析细胞对流和抗淋巴细胞感染的抗体的高变量区域。